Edralbrutinib (TG-1701) is an irreversible, highly specific, and potent inhibitor of Bruton’s tyrosine kinase (BTK). TG-1701 shows similar efficacy but greater selectivity compared to the first-in-class BTK inhibitor ibrutinib, with a Kd value of 3 nmol/L, in both in vitro and in vivo models of B-cell non-Hodgkin lymphoma (B-NHL).

MFI8 is a small molecule inhibitor of mitofusin-1 (MFN1) and mitofusin-2 (MFN2). It significantly reduces mitochondrial aspect ratio, inhibiting mitochondrial fusion and subsequently promoting mitochondrial fission and can be used in research on disorders with impaired mitochondrial dynamics.

MFI8 is a small molecule inhibitor of mitofusin-1 (MFN1) and mitofusin-2 (MFN2). It significantly reduces mitochondrial aspect ratio, inhibiting mitochondrial fusion and subsequently promoting mitochondrial fission and can be used in research on disorders with impaired mitochondrial dynamics.

Edralbrutinib (TG-1701) is an irreversible, highly specific, and potent inhibitor of Bruton’s tyrosine kinase (BTK). TG-1701 shows similar efficacy but greater selectivity compared to the first-in-class BTK inhibitor ibrutinib, with a Kd value of 3 nmol/L, in both in vitro and in vivo models of B-cell non-Hodgkin lymphoma (B-NHL).

Edralbrutinib (TG-1701) is an irreversible, highly specific, and potent inhibitor of Bruton’s tyrosine kinase (BTK). TG-1701 shows similar efficacy but greater selectivity compared to the first-in-class BTK inhibitor ibrutinib, with a Kd value of 3 nmol/L, in both in vitro and in vivo models of B-cell non-Hodgkin lymphoma (B-NHL).

Edralbrutinib (TG-1701) is an irreversible, highly specific, and potent inhibitor of Bruton’s tyrosine kinase (BTK). TG-1701 shows similar efficacy but greater selectivity compared to the first-in-class BTK inhibitor ibrutinib, with a Kd value of 3 nmol/L, in both in vitro and in vivo models of B-cell non-Hodgkin lymphoma (B-NHL).

TNG260 is an inhibitor of CoREST-selective deacetylase (CoreDAC) that inhibits HDAC1 with 10-fold selectivity over HDAC3. It decreases intratumoral neutrophil infiltration and exhibits immune-mediated cell killing.

TNG260 is an inhibitor of CoREST-selective deacetylase (CoreDAC) that inhibits HDAC1 with 10-fold selectivity over HDAC3. It decreases intratumoral neutrophil infiltration and exhibits immune-mediated cell killing.

TNG260 is an inhibitor of CoREST-selective deacetylase (CoreDAC) that inhibits HDAC1 with 10-fold selectivity over HDAC3. It decreases intratumoral neutrophil infiltration and exhibits immune-mediated cell killing.

Iruplinalkib (WX-0593) is a highly selective oral inhibitor of ALK and ROS1 tyrosine kinase. It exhibits potent and promising antitumor activity in advanced non-small cell lung cancer (NSCLC) with ALK or ROS1 rearrangement.